A5011844809- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Glioma Diagnosis and Treatment
- Radiation Therapy and Dosimetry
- Management of metastatic bone disease
- Breast Cancer Treatment Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Head and Neck Cancer Studies
- Radiation Dose and Imaging
- Cancer Diagnosis and Treatment
- Meningioma and schwannoma management
- Advances in Oncology and Radiotherapy
- Lung Cancer Treatments and Mutations
- Advanced MRI Techniques and Applications
- MRI in cancer diagnosis
- Renal cell carcinoma treatment
- Colorectal and Anal Carcinomas
- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Surgical Treatments
University of Brescia
2017-2025
Ospedale Sacro Cuore Don Calabria
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2011-2025
Varian Medical Systems (United States)
2023
Brescia University
2020-2022
Tehran University of Medical Sciences
2022
Humanitas University
2012-2020
University of Turin
2020
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2016-2020
Azienda Ospedaliero-Universitaria Careggi
2020
PURPOSE ARTO (ClinicalTrials.gov identifier: NCT03449719 ) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in patients with oligometastatic castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS All were affected by CRPC as defined three or less nonvisceral metastatic lesions. Patients randomly assigned 1:1 receive either AAP alone (control arm) concomitant SBRT...
Linac-based stereotactic radiosurgery or fractionated radiotherapy (SRS/FSRT) of multiple brain lesions using volumetric modulated arc therapy (VMAT) is typically performed by a multiple-isocenter approach, i.e. one isocenter per lesion, which time-demanding for the need independent setup verifications each isocenter. Here, we present our initial experience with new dedicated mono-isocenter technique non-coplanar arcs (HyperArc™, Varian Inc.) in terms plan comparison VMAT approach. From...
The aim of the present study is to evaluate impact metastases-directed stereotactic body radiotherapy in two groups oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant (oligo-CRPC). Inclusion criteria multicentre retrospective analysis were: (1) PC, defined as presence 1–3 lesions (bone or nodes) detected with choline positron emission tomography CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, metastases after a...
To test feasibility and safety of clinical usage Flattening Filter Free (FFF) beams for delivering ablative stereotactic body radiation therapy (SBRT) doses to various tumor sites, by means Varian TrueBeam™ (Varian Medical Systems).Seventy patients were treated with SBRT FFF: 51 lesions in the thorax (48 patients),10 liver, 9 isolated abdominal lymph node, adrenal gland or pancreas. Doses ranged from 32 75 Gy, depending on anatomical site volume lesion irradiate. Lung cumulative 48 delivered...
Unity Elekta is a unique magnetic resonance (MR)-linac that conjugates 1.5 Tesla MR unit with 7 MV flattening filter free accelerator.A prospective observational study for the clinical use of currently ongoing in our department. Herein, we present preliminary report on feasibility, quality life, and patient-reported outcomes measures (PROMs) localized prostate cancer (PC) treated stereotactic body radiotherapy (SBRT).The SBRT protocol consisted 35 Gy schedule delivered 5 fractions within 2...
To evaluate the feasibility and early side effects of a short course hypo-fractionated SBRT programme with Volumetric Modulated Arc Therapy (VMAT) Flattening Filter Free (FFF) beams.A prospective phase I-II study, started on February 2012. Inclusion criteria were: age ≤ 80 years, WHO-PS 2, PSA 20 ng/ml, histologically proven prostate adenocarcinoma, T1-T2 stage, no distant metastases, previous surgery other than TURP, malignant tumours in 5 IPSS 0-7. The schedule was 35 Gy alternative days....
Data in the literature suggest existence of oligometastatic disease, a state which metastases are limited number and site. Different kinds local therapies have been used for treatment recent years reports on use Stereotactic Ablative radiotherapy (SABR) emerging early results control promising.From October 2010 to February 2012, 76 consecutive patients 118 lung lesions were treated. SABR was performed case controlled primary tumor, long-term progression exclusion surgery, metastatic sites ≤...
Although the organ preservation strategy by breast-conserving surgery (BCS) followed radiation therapy (BCT) has revolutionized treatment approach of early stage breast cancer (BC), choice between options in this setting can still vary according to patient preferences. The aim present study was compare oncological outcome mastectomy versus patients treated a modern clinical outside trials. 7565 women diagnosed with invasive BC (pT1/2pN0/1) 1998 and 2014 were included (median follow-up: 95.2...
Background and purposeOligometastatic prostate cancer is a new emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective small phase 2 large difference across centers. Pending results ongoing trials, there clear need for more consistent indications radiotherapy practices.Material methodsA European Society...
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably defining lesions and guiding MDT within trials. <b>Methods:</b> We retrospectively identified PCa patients who had 5 or fewer nodal, bone, visceral metastases detected by choline prostate-specific membrane antigen (PSMA) PET/CT underwent stereotactic...